Metformin Therapy in Non-diabetic AAA Patients
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.
Also called NCT03507413
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT03507413
-
- Other papers using this trial's data
- MetAAA Trial Patients Receiving Metformin Therapy Show Limited Improvement in Quality of Life Compared to AAA Patients with Placebo Intake-A Double-Blind, Randomized, and Placebo-Controlled Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria
- Registry status
- Unknown status
Technical summary
Registry record NCT03507413. Randomized; quadruple masking; primary purpose treatment. Start 2018-09-26 (actual); primary completion 2024-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin Therapy in Non-diabetic AAA Patients
- Acronym
- MetAAA
- Condition
- Abdominal Aortic Aneurysm
- Intervention (Drug)
- Metformin Glucophage 500mg (IR) tablets M90
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Medical University of Vienna
- Collaborator
- Merck Serono GmbH, Germany
Record details
- Record id
cardio:ct-nct03507413- Content hash
7b63c0fe0821b9f5315989a08c8960bce53126aafdc2769e5ce2f1a62e25ab1f